Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down on Disappointing Earnings

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) gapped down prior to trading on Friday following a weaker than expected earnings announcement. The stock had previously closed at $292.42, but opened at $251.00. Bio-Rad Laboratories shares last traded at $261.01, with a volume of 350,825 shares.

The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.95%. The business had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same period last year, the company posted $2.90 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 3.9% on a year-over-year basis.

Bio-Rad Laboratories News Summary

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Management outlined a 2026 program to expand margins via operational improvements and cost actions, which could improve profitability over time. Bio‑Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance
• Positive Sentiment: Management reiterated a focus on operational fixes and provided a slide deck and detailed Q&A on the call — useful for modeling forward margin improvement timing and one‑time items. Q4 results presentation
• Neutral Sentiment: FY‑2026 revenue guidance is modest: management expects roughly flat to low‑single‑digit top‑line growth (about 0.5%–1.5%) with a revenue target around ~$2.6B — implies conservative near‑term growth expectations. Bio‑Rad Reports Fourth‑Quarter and Full‑Year 2025 Financial Results
• Neutral Sentiment: The company provided a full earnings call transcript and presentation that disclose drivers of the quarter and planned cost actions; these documents are important for forecasting the timing and magnitude of margin recovery. Earnings call transcript
• Negative Sentiment: Q4 EPS missed consensus: $2.51 actual vs. $2.57 expected, and revenue of $693.2M narrowly missed estimates — EPS declined from $2.90 a year ago, signaling pressure on short‑term earnings momentum. Q4 earnings miss
• Negative Sentiment: The company reported a negative net margin (reported -26.4%), which likely reflects discrete charges or restructuring that compressed reported profitability and increased investor uncertainty. Market summary and ratios
• Negative Sentiment: Market reaction was sharp: shares dropped with elevated volume after the print and guidance; the combination of an earnings miss and conservative/ muted revenue growth guidance likely triggered the sell‑off. Shares tumble after Q4 miss

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BIO shares. Wells Fargo & Company raised their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Citigroup upped their price target on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Finally, Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $358.50.

Institutional Trading of Bio-Rad Laboratories

Several institutional investors have recently added to or reduced their stakes in BIO. Royal Bank of Canada raised its stake in shares of Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Bio-Rad Laboratories by 45.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after buying an additional 32,874 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Bio-Rad Laboratories by 14.8% during the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock valued at $377,000 after purchasing an additional 199 shares during the last quarter. Jane Street Group LLC raised its stake in Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after buying an additional 18,239 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in Bio-Rad Laboratories by 42.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 3,023 shares of the medical research company’s stock valued at $730,000 after acquiring an additional 900 shares during the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

The company has a market cap of $6.93 billion, a P/E ratio of 9.20 and a beta of 1.18. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $305.47 and a two-hundred day simple moving average of $300.82.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.